BTIG Research Reaffirms “Neutral” Rating for Simulations Plus (NASDAQ:SLP)

Simulations Plus (NASDAQ:SLP)‘s stock had its “neutral” rating reissued by equities researchers at BTIG Research in a note issued to investors on Wednesday, Benzinga reports.

SLP has been the subject of several other research reports. Wall Street Zen downgraded Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings raised shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, July 10th. William Blair downgraded shares of Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. Finally, Craig Hallum lowered shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 target price on the stock. in a research report on Thursday, June 18th. Seven analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $17.25.

Simulations Plus Price Performance

NASDAQ SLP opened at $18.50 on Wednesday. The business has a fifty day moving average price of $18.40 and a two-hundred day moving average price of $16.61. Simulations Plus has a fifty-two week low of $11.09 and a fifty-two week high of $21.01. The stock has a market capitalization of $374.06 million, a PE ratio of 46.24 and a beta of 1.31.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.07. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.The company had revenue of $21.89 million for the quarter, compared to analyst estimates of $20.90 million.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SLP. GAMMA Investing LLC boosted its position in shares of Simulations Plus by 26.0% during the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after buying an additional 585 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Simulations Plus by 1.3% during the 1st quarter. Bank of New York Mellon Corp now owns 63,592 shares of the technology company’s stock valued at $752,000 after acquiring an additional 844 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Simulations Plus during the 2nd quarter worth $26,000. Hsbc Holdings PLC boosted its holdings in Simulations Plus by 6.1% during the 2nd quarter. Hsbc Holdings PLC now owns 28,116 shares of the technology company’s stock worth $520,000 after acquiring an additional 1,622 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Simulations Plus by 59.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock worth $53,000 after acquiring an additional 1,669 shares in the last quarter. 78.08% of the stock is owned by institutional investors and hedge funds.

About Simulations Plus

Simulations Plus, Inc develops software and provides services that support pharmaceutical research, drug development and regulatory decision-making. Its technologies help scientists model how drug compounds behave in the body, assess formulation and delivery characteristics, and evaluate potential safety and efficacy outcomes.

The company’s software portfolio includes GastroPlus, a platform for physiologically based pharmacokinetic and pharmacodynamic modeling; ADMET Predictor, which forecasts absorption, distribution, metabolism, excretion and toxicity properties; and DDDPlus, which simulates drug dissolution and dosage-form performance.